GlassScriptPhysician profile
Nasser Nasralla
NPI 1417444019
$1,793.87
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,228 · 2022: $566.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $362.37 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $266.97 | 2021-2022 | |
| Celgene Corporation | $219.30 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $187.89 | 2021-2022 | |
| Abbott Laboratories | $130.57 | 2021 | |
| Abbvie INC. | $120.59 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.56 | 2022 | |
| Glaxosmithkline, LLC. | $116.82 | 2021 | |
| Alexion Pharmaceuticals, INC. | $113.21 | 2022 | |
| Merck Sharp & Dohme LLC | $80.92 | 2021 | |
| Philips North America LLC | $76.67 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasser Nasralla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.